Newsletter
Aurobindo Pharma’s wholly-owned subsidiary, Aurobindo Pharma USA, has entered into a definitive agreement to acquire Lannett Company LLC from Lannett Seller Holdco.
The deets: the deal is valued at $250 million on a cash-free, debt-free basis. Lannett is a U.S.-based manufacturer and supplier of complex generic pharmaceuticals. The company specialises in non-opioid controlled substances, particularly treatments for ADHD, and has launched several generic liquid formulations in the market.
The why: this strategic acquisition provides Aurobindo with:
- a complementary portfolio of profitable products
- a growing Contract Development and Manufacturing Organisation (CDMO) business
- a U.S.-based manufacturing facility with significant excess capacity and room for future expansion
Why it matters: Aurobindo currently has limited exposure in the ADHD therapeutics space, and this acquisition offers strategic diversification into a high-value segment.
